×
About 12,684 results

ALLMedicine™ Myelodysplastic Syndromes Center

Research & Reviews  6,059 results

A novel RUNX1 mutation with ANKRD26 dysregulation is related to thrombocytopenia in a s...
https://doi.org/10.1007/s40520-020-01709-7
Aging Clinical and Experimental Research; Ferrari S, Regazzo D et. al.

Sep 18th, 2020 - Aging is associated with a higher risk of developing malignant diseases, including myelodysplastic syndromes, clonal disorders characterised by chronic cytopenias (anaemia, neutropenia and thrombocytopenia) and abnormal cellular maturation. Myelod...

No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: a re...
https://doi.org/10.1111/cas.14653
Cancer Science; Toriyama E, Hata T et. al.

Sep 17th, 2020 - The efficacy of azacitidine (AZA) on survival of lower risk (LR) - myelodysplastic syndromes (MDS) is controversial. To address this issue, we retrospectively evaluated the long-term survival benefit of AZA for patients with LR-MDS defined by Inte...

The neuroprotective action of lenalidomide on rotenone model of Parkinson's Disease: Ne...
https://doi.org/10.1016/j.neulet.2020.135308
Neuroscience Letters; Cankara FN, Günaydın C et. al.

Sep 15th, 2020 - Lenalidomide is a centrally active thalidomide analog that has potent anti-inflammatory and antiangiogenic activities. Currently, it is primarily used in the treatment of multiple myeloma and myelodysplastic syndromes. However, recent studies have...

Megakaryocytes, erythropoietic and granulopoietic cells express CAL2 antibody in myelop...
https://doi.org/10.1111/iep.12375
International Journal of Experimental Pathology REFERENCES; Ali H, Puccio I et. al.

Sep 15th, 2020 - Testing for the CALR mutation is included in the updated WHO criteria for essential thrombocythaemia (ET) and primary myelofibrosis (PMF). We report on the application of the CAL2 monoclonal antibody, raised against the mutated CALR gene to myeloi...

The burden of immune-mediated refractoriness to platelet transfusions in myelodysplasti...
https://doi.org/10.1111/trf.16029
Transfusion REFERENCES; Cheok KPL, Chhetri R et. al.

Sep 9th, 2020 - Up to 65% of patients with myelodysplastic syndromes (MDS) have thrombocytopenia and require platelet (PLT) transfusion. The current standard of practice is to provide random- or single-donor PLT transfusion and manage PLT refractoriness (PLT-R) i...

see more →

Guidelines  31 results

Considerable Variation Exists in Receipt of Complete Diagnostic Evaluations for Myelodysplastic Syndromes Among Medicare Patients
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200129/full/

May 12th, 2020 - A substantial proportion of Medicare patients with myelodysplastic syndromes (MDS) do not undergo a complete diagnostic evaluation (CDE), including a bone marrow biopsy, to confirm their disease (Abstract 7555).

Hematology Quality Metrics
http://www.hematology.org/Clinicians/Guidelines-Quality/503.aspx
Allen, S.

Feb 20th, 2018 - These clinical performance measures are designed for individual quality improvement. Some of the measures may also be appropriate for accountability if appropriate sample sizes and implementation rules are achieved.

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0007
Journal of the National Comprehensive Cancer Network : JNCCN; Greenberg PL, Stone RM et. al.

Jan 3rd, 2017 - The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the p...

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment a...
https://doi.org/10.1093/annonc/mdu180
Annals of Oncology : Official Journal of the European Society for Medical Oncology; Fenaux P, Haase D et. al.

Sep 3rd, 2014 - Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2014|Fenaux P,Haase D,Sanz GF,Santini V,Buske C,|diagnosis,therapy,standards,

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from...
http://www.bloodjournal.org/content/122/17/2943
Malcovati, L.,et al.

Oct 23rd, 2013 - Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program. A systematic review of the lit.

see more →

Drugs  53 results see all →

Clinicaltrials.gov  6,273 results

A novel RUNX1 mutation with ANKRD26 dysregulation is related to thrombocytopenia in a s...
https://doi.org/10.1007/s40520-020-01709-7
Aging Clinical and Experimental Research; Ferrari S, Regazzo D et. al.

Sep 18th, 2020 - Aging is associated with a higher risk of developing malignant diseases, including myelodysplastic syndromes, clonal disorders characterised by chronic cytopenias (anaemia, neutropenia and thrombocytopenia) and abnormal cellular maturation. Myelod...

No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: a re...
https://doi.org/10.1111/cas.14653
Cancer Science; Toriyama E, Hata T et. al.

Sep 17th, 2020 - The efficacy of azacitidine (AZA) on survival of lower risk (LR) - myelodysplastic syndromes (MDS) is controversial. To address this issue, we retrospectively evaluated the long-term survival benefit of AZA for patients with LR-MDS defined by Inte...

The neuroprotective action of lenalidomide on rotenone model of Parkinson's Disease: Ne...
https://doi.org/10.1016/j.neulet.2020.135308
Neuroscience Letters; Cankara FN, Günaydın C et. al.

Sep 15th, 2020 - Lenalidomide is a centrally active thalidomide analog that has potent anti-inflammatory and antiangiogenic activities. Currently, it is primarily used in the treatment of multiple myeloma and myelodysplastic syndromes. However, recent studies have...

Megakaryocytes, erythropoietic and granulopoietic cells express CAL2 antibody in myelop...
https://doi.org/10.1111/iep.12375
International Journal of Experimental Pathology REFERENCES; Ali H, Puccio I et. al.

Sep 15th, 2020 - Testing for the CALR mutation is included in the updated WHO criteria for essential thrombocythaemia (ET) and primary myelofibrosis (PMF). We report on the application of the CAL2 monoclonal antibody, raised against the mutated CALR gene to myeloi...

The burden of immune-mediated refractoriness to platelet transfusions in myelodysplasti...
https://doi.org/10.1111/trf.16029
Transfusion REFERENCES; Cheok KPL, Chhetri R et. al.

Sep 9th, 2020 - Up to 65% of patients with myelodysplastic syndromes (MDS) have thrombocytopenia and require platelet (PLT) transfusion. The current standard of practice is to provide random- or single-donor PLT transfusion and manage PLT refractoriness (PLT-R) i...

see more →

News  259 results

Considerable Variation Exists in Receipt of Complete Diagnostic Evaluations for Myelodysplastic Syndromes Among Medicare Patients
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200129/full/

May 12th, 2020 - A substantial proportion of Medicare patients with myelodysplastic syndromes (MDS) do not undergo a complete diagnostic evaluation (CDE), including a bone marrow biopsy, to confirm their disease (Abstract 7555).

Genetic analysis highlights value of germline variants in MDS, AML
https://www.mdedge.com/hematology-oncology/article/208332/aml/genetic-analysis-highlights-value-germline-variants-mds-aml?channel=39313
Caleb Rans

Sep 18th, 2019 - Germline DDX41 mutations were found to be relatively prevalent and showed favorable outcomes in a cohort of patients with myelodysplastic syndromes or acute myeloid leukemia, according to a genetic analysis. Jezperklauzen/ThinkStock The results de.

Cancer centers announce new faculty
https://www.mdedge.com/hematology-oncology/article/206202/business-medicine/cancer-centers-announce-new-faculty?channel=59288
Jennifer Smith

Aug 12th, 2019 - Jorge E. Cortes, MD, is set to become director of the Georgia Cancer Center in Augusta on Sept.

Antibody targeting ‘do not eat me’ signals is active in AML, MDS
https://www.mdedge.com/hematology-oncology/article/202763/aml/antibody-targeting-do-not-eat-me-signals-active-aml-mds?channel=253
Andrew D. Bowser

Jun 11th, 2019 - CHICAGO – A novel antibody against CD47 – the “do not eat me” protein – is well tolerated and active in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), according to initial results of a phase 1b study. Combined with.

More abnormal cells linked to poorer ASCT outcomes in MDS
https://www.mdedge.com/hematology-oncology/article/200182/transplantation/more-abnormal-cells-linked-poorer-asct-outcomes?channel=341
Jennifer Smith

May 3rd, 2019 - NEWPORT BEACH, CALIF. – Researchers say they’ve found an association between the percentage of cytogenetically abnormal cells at allogeneic stem cell transplant (ASCT) and posttransplant outcomes in patients with myelodysplastic syndromes (MDS).

see more →

Patient Education  9 results see all →